RxDoctor Payments Data

Mark Ortiz, PA

Neurology · New Haven, CTNPI 1740796465

Payments from drug & device makers

$9,836in general payments, 2019–2025

Across 457 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$667
  • Biohaven Pharmaceuticals, Inc.$504
  • UCB, Inc.$473
  • Amgen$441
  • Harmony Biosciences LLC$410
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$9,803100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,836 in reported general payments places this provider in the 65th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$9,317
Medicare patients
27
Services billed
898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant19$33,356
Nurtec OdtRimegepant Sulfate22$32,717
Emgality PenGalcanezumab-Gnlm20$17,137
QuliptaAtogepant11$16,236
BotoxOnabotulinumtoxina12$14,921
Ajovy AutoinjectorFremanezumab-Vfrm11$10,934
ElyxybCelecoxib13$10,230
Entacapone16$3,379
Galantamine ErGalantamine Hbr13$1,546
Memantine Hcl72$1,457
Levetiracetam57$1,343
Divalproex Sodium11$1,338
Donepezil Hcl114$1,017
Pregabalin47$966
Gabapentin65$812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$2,075$64,51342 claims
PfizerNurtec Odt$228$32,71722 claims
Scilex Pharmaceuticals Inc.Elyxyb$338$10,23013 claims
Upsher-smith Laboratories LLCTopiramate$74$60042 claims
Almatica Pharma LLCSertraline Hcl$97$17418 claims
Lilly USA, LLCOlanzapine$214$6311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 280 neurology providers in Connecticut.

Other neurology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →